2cureX prepares for market launch of IndiTreat™ in 2020 – international Chief Business Officer is recruited to lead the process
2cureX AB (Nasdaq First North: 2CUREX), a MedTech company that has developed the IndiTreat™ test that uniquely matches the effective combination therapy with the individual cancer patient, announces today the strengthening of its Management Team with Mr. Maarten van der Linden as Chief Business Officer (CBO).
Prior to join 2cureX, Maarten van der Linden spent most of his career in the pharmaceutical and diagnostics industry, with a focus on commercialising products within the oncology field. Mr. Van der Linden was until recently Senior Director of Marketing for Europe Middle East and Africa (EMEA) at Abbott Laboratories, where under his leadership the Molecular Diagnostics Division over a period of three consecutive years outperformed the diagnostic market growth. Before that, he was a Senior Director of Global marketing at Agilent and Regional Business Manager for new Products at Merck, Sharp & Dohme covering multiple disease areas, including oncology. Maarten holds an Executive MBA from Henley Business School, UK.
“Mr. Maarten van der Linden is an excellent addition to our management team: his comprehensive business expertise in preparing organizations for new product launches and in building the market for such products in the oncology field is of paramount importance to 2cureX” stated Ole Thastrup, the CEO of 2cureX. He added: “Our ability to recruit Mr. van der Linden endorses the uniqueness of IndiTreat™ in cancer therapy, and a belief that 2cureX can develop into a global player in the field of individualized cancer treatment.”
“I am very pleased and excited to join the newly listed 2cureX” said Maarten van der Linden, newly appointed CBO. He added “2cureX is in a strong position: with a unique test, a recently launched clinical validation study, and a comprehensive network of European partner hospitals – this venture proves to be an attractive package for a business developer. I believe that 2cureX has the opportunity to introduce the IndiTreat™ test as a general tool in the oncologist’s tool box to select the optimal treatment for cancer patients. I am excited to be part of the 2cureX journey and help in making key stakeholders aware of IndiTreat™ and thereby assisting in increasing the value of the company.”
For more information about 2cureX:
Ole Thastrup, VD
Phone: +45 22 11 53 99
2cureX has developed IndiTreat ™ (Individual Treatment Design) - a patented method for selecting the right drug for the right patient, thereby improving cancer treatment. IndiTreat ™ is developed and clinically tested in more than 900 patients with promising results. Initially, IndiTreat™ is targeted towards colorectal cancer; but the method is applicable to additional cancer indications (e.g. ovarian, breast and kidney cancer). The company is listed at the Nasdaq First North stock exchange in Stockholm.